ADARx
ADRX

ADARx (ADRX) stock price, chart and financials

Price chart

−26.82% over 1Y
Sep 25, 2026Low $12.82 · High $20.64Nov 19, 2026

Financials

Net margin
−1445.04%

Company profile

Adarx Pharmaceuticals Inc is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. Its pipeline includes three clinical-stage programs and two advanced preclinical programs. The three hepatic-targeted programs are agazisiran, onvuzosiran, and ADX-626, while the two extrahepatic-targeted programs are ADX-077 and ADX-199.

Frequently asked questions

  • Is ADARx (ADRX) profitable?

    No. ADARx reported a net loss of $98.1M over the trailing twelve months.

  • How much revenue does ADARx (ADRX) make?

    ADARx generated $6.8M in revenue over the trailing twelve months, up 42.57% year over year.

  • How do I buy stock in ADARx (ADRX)?

    ADRX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.

Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.